$VXRT
Vaxart, Inc. Stock $vxrt

$vxrt Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143774921025287 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$74.00K	$200.0K	$265.0K
YoY Change	-79.21%	-24.53%	-41.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.754M	$5.042M	$4.190M
YoY Change	12.16%	20.33%	186.99%
% of Gross Profit
Research & Development	$15.53M	$12.41M	$4.616M
YoY Change	80.79%	168.83%	24.32%
% of Gross Profit
Depreciation & Amortization	$1.198M	$211.0K	$34.00K
YoY Change	39.3%	520.59%	-74.05%
% of Gross Profit
Operating Expenses	$24.29M	$17.45M	$7.854M
YoY Change	77.07%	122.19%	51.97%
Operating Profit		-$17.25M	-$7.589M
YoY Change		127.32%	60.99%
Interest Expense	$23.00K	$26.00K
YoY Change	130.0%
% of Operating Profit
Other Income/Expense, Net	-$343.0K	-$337.0K	-$470.0K
YoY Change	-27.02%	-28.3%	-8.74%
Pretax Income	-$20.75M	-$17.56M	-$8.059M
YoY Change	50.01%	117.92%	54.12%
Income Tax	$18.00K	$21.00K	$26.00K
% Of Pretax Income
Net Earnings	-$20.76M	-$17.58M	-$8.085M
YoY Change	49.8%	117.48%	53.71%
Net Earnings / Revenue	-28059.46%	-8791.5%	-3050.94%
Basic Earnings Per Share		-$0.14
Diluted Earnings Per Share	-$165.5K	-$141.8K	-$75.10K
COMMON SHARES
Basic Shares Outstanding	125.5M	122.8M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$166.5M	$187.7M	$133.4M
YoY Change	31.23%	40.68%	580.61%
Cash & Equivalents	$143.7M	$167.2M	$133.4M
Short-Term Investments	$22.74M	$20.44M
Other Short-Term Assets	$2.609M	$4.441M	$1.700M
YoY Change	100.69%	161.24%	54.55%
Inventory
Prepaid Expenses
Receivables	$71.00K	$190.0K	$250.0K
Other Receivables			$300.0K
Total Short-Term Assets	$169.2M	$192.3M	$135.6M
YoY Change	31.62%	41.82%	537.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.601M	$5.427M	$662.0K
YoY Change	346.01%	719.79%	-54.94%
Goodwill	$4.508M
YoY Change
Intangibles	$10.62M	$14.06M	$15.79M
YoY Change	-30.84%	-10.97%	-9.88%
Long-Term Investments	$16.21M	$16.28M
YoY Change
Other Assets	$890.0K	$828.0K	$72.00K
YoY Change	139.25%	1050.0%	-50.34%
Total Long-Term Assets	$52.00M	$48.84M	$19.12M
YoY Change	116.21%	155.43%	-10.83%
TOTAL ASSETS
Total Short-Term Assets	$169.2M	$192.3M	$135.6M
Total Long-Term Assets	$52.00M	$48.84M	$19.12M
Total Assets	$221.2M	$241.1M	$154.7M
YoY Change	44.95%	55.86%	262.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.872M	$3.745M	$1.871M
YoY Change	81.53%	100.16%	78.36%
Accrued Expenses	$5.064M	$4.387M	$3.724M
YoY Change	5.52%	17.8%	132.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$800.0K	$3.100M	$3.000M
YoY Change	-71.43%	3.33%	20.0%
Total Short-Term Liabilities	$10.78M	$12.60M	$10.30M
YoY Change	-8.33%	22.26%	12.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$171.0K	$156.0K
YoY Change	56.88%
Total Long-Term Liabilities	$171.0K	$156.0K	$0.00
YoY Change	56.88%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.78M	$12.60M	$10.30M
Total Long-Term Liabilities	$171.0K	$156.0K	$0.00
Total Liabilities	$33.64M	$36.19M	$23.03M
YoY Change	15.28%	57.12%	-3.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$219.4M	-$198.6M	-$135.0M
YoY Change	47.33%	47.08%	22.46%
Common Stock	$407.0M	$403.5M	$266.7M
YoY Change	49.46%	51.31%	106.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$187.5M	$204.9M	$131.7M
YoY Change
Total Liabilities & Shareholders Equity	$221.2M	$241.1M	$154.7M
YoY Change	44.95%	55.86%	262.36%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$20.76M	-$17.58M	-$8.085M
YoY Change	49.8%	117.48%	53.71%
Depreciation, Depletion And Amortization	$1.198M	$211.0K	$34.00K
YoY Change	39.3%	520.59%	-74.05%
Cash From Operating Activities	-$15.81M	-$14.27M	-$9.250M
YoY Change	46.83%	54.24%	113.63%
INVESTING ACTIVITIES
Capital Expenditures	-$1.015M	-$1.324M	-$310.0K
YoY Change	12.78%	327.1%	138.46%
Acquisitions
YoY Change
Other Investing Activities	-$7.162M	-$3.088M	$0.00
YoY Change
Cash From Investing Activities	-$8.177M	-$4.412M	-$310.0K
YoY Change	808.56%	1323.23%	138.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	505.0K	20.64M	98.61M
YoY Change	-90.1%	-79.07%	1170.75%
NET CHANGE
Cash From Operating Activities	-15.81M	-14.27M	-9.250M
Cash From Investing Activities	-8.177M	-4.412M	-310.0K
Cash From Financing Activities	505.0K	20.64M	98.61M
Net Change In Cash	-23.49M	1.965M	89.05M
YoY Change	257.47%	-97.79%	2598.48%
FREE CASH FLOW
Cash From Operating Activities	-$15.81M	-$14.27M	-$9.250M
Capital Expenditures	-$1.015M	-$1.324M	-$310.0K
Free Cash Flow	-$14.80M	-$12.94M	-$8.940M
YoY Change	49.94%	44.78%	112.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5752000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
	vxrt	Impairment Of Property And Equipment ImpairmentOfPropertyAndEquipment	0	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	433000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2021Q3	vxrt	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	0	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	125496066
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125294816
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125294816
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110271093
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110271093
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	746000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167231000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126870000	USD
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	20438000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	190000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	334000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4441000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1327000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	192300000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	128531000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	16282000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5427000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12237000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6838000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14062000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15361000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	828000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	372000	USD
CY2021Q3	us-gaap	Assets Assets	241136000	USD
CY2020Q4	us-gaap	Assets Assets	152582000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3745000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2133000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1345000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2052000	USD
CY2021Q3	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	3118000	USD
CY2020Q4	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	2779000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4387000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4799000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12595000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11763000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11397000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5156000	USD
CY2021Q3	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12040000	USD
CY2020Q4	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12150000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	156000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	109000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	36188000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	29178000	USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	403525000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	272274000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198587000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148881000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	204948000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123404000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	241136000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152582000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	200000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	265000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	818000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3690000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12409000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4616000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33219000	USD
	us-gaap	Operating Expenses OperatingExpenses	49355000	USD
	us-gaap	Operating Expenses OperatingExpenses	20499000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17251000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7589000	USD
CY2020Q3	us-gaap	Restructuring Charges RestructuringCharges	-952000	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	-849000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	17451000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	7854000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11272000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5042000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4190000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16136000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10076000	USD
CY2021Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48537000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16809000	USD
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	26000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	58000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	69000	USD
CY2021Q3	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	337000	USD
CY2020Q3	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	464000	USD
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	1137000	USD
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	1401000	USD
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17562000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8059000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49617000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18154000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	89000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	205000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17583000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-8085000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18359000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123984141
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107718578
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120110780
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81121045
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17583000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-8085000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18359000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17577000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8085000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49709000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18359000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	199782000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20296000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	348000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2099000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	6000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17583000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	204948000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123404000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	122210000	USD
	vxrt	Stock Issued During Period Value Exercise Of Common Stock Warrants StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants	1849000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1240000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5954000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49706000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	204948000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	40235000	USD
CY2020Q3	vxrt	Stock Issued During Period Value Exercise Of Common Stock Warrants StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants	1293000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	286000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	915000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-8085000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	131678000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	12952000	USD
	vxrt	Stock Issued During Period Value Exercise Of Common Stock Warrants StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants	25951000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	402000	USD
	vxrt	Adjustments To Additional Paid In Capital Disgorgement Of Shortswing Profits Net Of Costs AdjustmentsToAdditionalPaidInCapitalDisgorgementOfShortswingProfitsNetOfCosts	652000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3871000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18359000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	131678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18359000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3010000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1846000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	55000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5954000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3871000	USD
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	1137000	USD
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	1401000	USD
	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	908000	USD
	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	3027000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-144000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3369000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3570000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1384000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1483000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	810000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1617000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1511000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44018000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40920000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-318000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1849000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	25951000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1240000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	402000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12984000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4142000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	321000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	41278000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4500000	USD
	vxrt	Proceeds From Disgorgement Of Shortswing Profits Net Of Costs ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts	0	USD
	vxrt	Proceeds From Disgorgement Of Shortswing Profits Net Of Costs ProceedsFromDisgorgementOfShortswingProfitsNetOfCosts	652000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125299000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133214000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40361000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	119912000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126870000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13526000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	167231000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133438000	USD
	vxrt	Issuance Of Warrants To Placement Agents Designees IssuanceOfWarrantsToPlacementAgentsDesignees	0	USD
	vxrt	Issuance Of Warrants To Placement Agents Designees IssuanceOfWarrantsToPlacementAgentsDesignees	453000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6939000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1022000	USD
	vxrt	Leaserelated Assets And Liabilities Derecognized On Early Termination And Modification Of Leases LeaserelatedAssetsAndLiabilitiesDerecognizedOnEarlyTerminationAndModificationOfLeases	235000	USD
	vxrt	Leaserelated Assets And Liabilities Derecognized On Early Termination And Modification Of Leases LeaserelatedAssetsAndLiabilitiesDerecognizedOnEarlyTerminationAndModificationOfLeases	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	289000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	213000	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and available-for-sale investments. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits since inception.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2021Q3	us-gaap	Investments And Cash InvestmentsAndCash	203954000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2021Q3	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	203951000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167231000	USD
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	20438000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	16282000	USD
CY2020Q4	us-gaap	Investments And Cash InvestmentsAndCash	126870000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	USD
CY2020Q4	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	126870000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126870000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6406000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2053000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	979000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	573000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5427000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	211000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	34000	USD
	us-gaap	Depreciation Depreciation	406000	USD
	us-gaap	Depreciation Depreciation	78000	USD
	vxrt	Impairment Of Property And Equipment ImpairmentOfPropertyAndEquipment	0	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12237000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6838000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20380000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20380000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6318000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5019000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14062000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15361000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0926	pure
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	433000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	433000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1731000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1732000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1732000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1731000	USD
CY2021Q3	vxrt	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	6703000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14062000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2084000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1618000	USD
CY2021Q3	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	725000	USD
CY2020Q4	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	1772000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	782000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	777000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	796000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	632000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4387000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4799000	USD
CY2021Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2020Q4	vxrt	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	219000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M1D
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	556000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2256000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1773000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1835000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2145000	USD
CY2021Q3	vxrt	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	9622000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18187000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5445000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	12742000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1345000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11397000	USD
CY2021Q3	vxrt	Lessee Operating Lease Lease Not Yet Commenced LesseeOperatingLeaseLeaseNotYetCommenced	14900000	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q3	vxrt	Lessee Finance Lease Number Of Leases LesseeFinanceLeaseNumberOfLeases	0	pure
CY2021Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	16000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	651000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	235000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1824000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	636000	USD
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	101000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	232000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	313000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	29000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	937000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	53000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	-0	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	54000	USD
	us-gaap	Sublease Income SubleaseIncome	36000	USD
	us-gaap	Sublease Income SubleaseIncome	163000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	1065000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	214000	USD
	us-gaap	Lease Cost LeaseCost	2957000	USD
	us-gaap	Lease Cost LeaseCost	536000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	970000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	243000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2800000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	717000	USD
CY2021Q3	us-gaap	Purchase Obligation PurchaseObligation	18200000	USD
	us-gaap	Dividends Dividends	0	USD
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16348934
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9288870
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	232434
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1230863
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6813033
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	8900000
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants	4122438
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4122438
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.24
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	771344
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited	554317
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	574054
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.44
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Canceled ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	36315
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.42
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6562742
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9553758
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.74
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9553758
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32100000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3665542
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.67
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M7D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	20100000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1200000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	771344
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4600000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	402000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	305179
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120110780
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81121045
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-17583000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-8085000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18359000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123984141
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107718578
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8697187
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8129823
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8096631
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23158593

Files In Submission

Name	View Source	Status
0001437749-21-025287-index-headers.html	Edgar Link	pending
0001437749-21-025287-index.html	Edgar Link	pending
0001437749-21-025287.txt	Edgar Link	pending
0001437749-21-025287-xbrl.zip	Edgar Link	pending
ex_279088.htm	Edgar Link	pending
ex_279089.htm	Edgar Link	pending
ex_290201.htm	Edgar Link	pending
ex_290201img001.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipetwooneqthree.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vxrt-20210930.xsd	Edgar Link	pending
vxrt-20210930_cal.xml	Edgar Link	unprocessable
vxrt-20210930_def.xml	Edgar Link	unprocessable
vxrt-20210930_lab.xml	Edgar Link	unprocessable
vxrt-20210930_pre.xml	Edgar Link	unprocessable
vxrt20210930_10q.htm	Edgar Link	pending
vxrt20210930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VXRT
Vaxart, Inc. Stock $vxrt

2021 Q4 Form 10-Q Financial Statement

#000143774921025287 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT Vaxart, Inc. Stock $vxrt

2021 Q4 Form 10-Q Financial Statement

#000143774921025287 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT
Vaxart, Inc. Stock $vxrt